A low dose of ketamine is safe and effective for treating children with ADNP syndrome
The research was led by researchers from the Seaver Autism Center for Research and Treatment at Mount Sinai and published online in Human Genetics and Genomic Advances. Ketamine was approved in the United States in 1970. Studies in animal models suggest that low-dose ketamine may be neuroprotective and increase the expression of the ADNP gene. […]
